- Home
- CAPT vs HOOK Comparison
CAPT vs HOOK Comparison
Compare CAPT & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- HOOK
- Stock Information
- Founded
- CAPT 2005
- HOOK 2011
- Country
- CAPT South Korea
- HOOK United States
- Employees
- CAPT N/A
- HOOK N/A
- Industry
- CAPT Blank Checks
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- HOOK Health Care
- Exchange
- CAPT Nasdaq
- HOOK Nasdaq
- Market Cap
- CAPT 16.0M
- HOOK 15.3M
- IPO Year
- CAPT N/A
- HOOK 2019
- Fundamental
- Price
- CAPT $1.54
- HOOK $1.19
- Analyst Decision
- CAPT
- HOOK Buy
- Analyst Count
- CAPT 0
- HOOK 4
- Target Price
- CAPT N/A
- HOOK $10.67
- AVG Volume (30 Days)
- CAPT 357.6K
- HOOK 60.2K
- Earning Date
- CAPT 01-01-0001
- HOOK 08-07-2025
- Dividend Yield
- CAPT N/A
- HOOK N/A
- EPS Growth
- CAPT N/A
- HOOK N/A
- EPS
- CAPT N/A
- HOOK N/A
- Revenue
- CAPT $17,389,944.00
- HOOK $9,351,000.00
- Revenue This Year
- CAPT N/A
- HOOK N/A
- Revenue Next Year
- CAPT N/A
- HOOK N/A
- P/E Ratio
- CAPT N/A
- HOOK N/A
- Revenue Growth
- CAPT 84.70
- HOOK N/A
- 52 Week Low
- CAPT $0.37
- HOOK $0.72
- 52 Week High
- CAPT $2.88
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- CAPT 71.95
- HOOK 37.08
- Support Level
- CAPT $1.14
- HOOK $1.13
- Resistance Level
- CAPT $1.21
- HOOK $1.25
- Average True Range (ATR)
- CAPT 0.08
- HOOK 0.06
- MACD
- CAPT 0.02
- HOOK -0.01
- Stochastic Oscillator
- CAPT 86.54
- HOOK 26.94
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.